Bristol Myers (BMY) Addresses Adamilparant Trial Fatality as Shares Dip 4%

gurufocus.com · 2026-10-12

On October 12, 2026, Bristol Myers Squibb Co (NYSE: BMY) informed Bloomberg that a recent patient fatality in the adamilparant Phase 3 trial is unlikely related

TickrTrends take: Bristol Myers Squibb faces investor scrutiny following a fatality in its Adamilparant trial, which contributed to a 4% share price decline. Given that TickrTrends currently assesses BMY as overvalued, the trial setback compounds concerns about whether the company's current market valuation appropriately reflects execution risks in its clinical pipeline. Shareholders should monitor how this event affects the company's drug development timelines and whether upcoming trial results or regulatory communications lead to valuation reassessment.

Read the full story at gurufocus.com →